IPAMOR-PURE (Ipamorelin) by Meditech is a pharmaceutical-grade selective Growth Hormone Releasing Peptide formulated as a lyophilized injectable peptide at 2 mg per vial. Ipamorelin is a synthetic pentapeptide growth hormone secretagogue with an established research history in neuroendocrinological and peptide pharmacology literature, distinguished from other GHRP compounds by its selective pituitary GH stimulation profile — documented to produce growth hormone release without concurrent significant elevation of cortisol, prolactin, or ACTH in comparative peptide research, representing a pharmacologically cleaner secretagogue profile relative to earlier generation GHRPs such as GHRP-2 and GHRP-6.
 
✔ Key Research Insights
Studied for its selective growth hormone secretagogue activity, with documented stimulation of pituitary somatotroph GH release in research subjects without significant concurrent elevation of cortisol, prolactin, or ACTH — a selectivity profile consistently distinguished in comparative GHRP pharmacology research
Investigated for its downstream effects on IGF-1 production following GH stimulation, with associated influences on lean mass parameters and tissue repair mechanisms documented in peptide pharmacology observations
Researched for its influence on metabolic parameters and body composition indices in clinical observations, mediated through selective growth hormone secretagogue activity in documented subject populations
Examined for its effects on recovery markers, sleep architecture quality, and cellular regeneration parameters across peptide research literature
Documented for its favorable tolerability profile relative to non-selective GHRP compounds in comparative peptide research, with minimal cortisol and prolactin elevation noted as a pharmacologically distinct characteristic in neuroendocrinological literature
Researched for its effects on skin collagen synthesis, hair follicle parameters, and dermal cellular regeneration in documented peptide research observations
Manufactured by Meditech to pharmaceutical-grade purity and lyophilized peptide formulation standards
 
📦 Product Specifications
Manufacturer: Meditech
Product: IPAMOR-PURE
Molecule: Ipamorelin
Concentration: 2 mg per vial
Appearance: Lyophilized white powder
Form: Injectable peptide requiring reconstitution prior to administration
Dosage considerations may vary. Consulting a qualified professional is recommended.
 
⚙ How It Works
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that functions as a selective agonist at the growth hormone secretagogue receptor type 1a (GHS-R1a) — the ghrelin receptor — located on pituitary somatotroph cells and in the hypothalamus. In research subjects, ipamorelin binding to GHS-R1a stimulates pulsatile growth hormone release from the anterior pituitary gland in a manner that closely mimics endogenous GH secretion patterns, avoiding the supraphysiological cortisol, prolactin, and ACTH elevations documented with less selective GHRP compounds in comparative neuroendocrinological research. This receptor selectivity profile is attributed in pharmacological research to ipamorelin's distinct binding characteristics at the GHS-R1a relative to earlier generation GHRPs, producing GH stimulation through a cleaner endocrine signaling pathway with documented minimal off-target pituitary hormone activation. The resulting elevation of circulating growth hormone subsequently stimulates hepatic IGF-1 production, with downstream effects on protein synthesis, cellular regeneration, fat metabolism, and recovery parameters documented across peptide pharmacology research literature. Ipamorelin is frequently examined in combination research protocols with GHRH analogues such as CJC-1295, as the two peptide classes act through complementary and potentially synergistic receptor pathways — GHRH receptor and GHS-R1a respectively — to amplify pituitary GH output in documented combination peptide research. Reconstitution with bacteriostatic water is standard protocol prior to subcutaneous administration in documented research settings, with lyophilized storage ensuring peptide stability and bioactivity prior to use.
 
⭐ Product Overview
Manufactured by Meditech to pharmaceutical-grade purity and lyophilized peptide formulation standards
Selective GHS-R1a agonist with a well-documented favorable hormonal selectivity profile — GH stimulation without significant cortisol, prolactin, or ACTH elevation — distinguishing ipamorelin from non-selective GHRP compounds in comparative neuroendocrinological research
Frequently examined in combination protocols with GHRH analogues for potentially synergistic pituitary GH stimulation effects documented in comparative peptide pharmacology research
Widely referenced in neuroendocrinological and peptide pharmacology research under the ipamorelin and selective GHRP designations
Available in lyophilized vial format requiring reconstitution prior to subcutaneous administration per standard peptide research protocols